title: Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment.
abstract: BACKGROUND
  Patients with amnestic mild cognitive impairment (MCI) demonstrate decline in everyday function. In this study, we investigated whether whole brain atrophy and apolipoprotein E (APOE) genotype are associated with the rate of functional decline in MCI.
  
  
  METHODS
  Participants were 164 healthy controls, 258 MCI patients, and 103 patients with mild Alzheimer's disease (AD), enrolled in the Alzheimer's Disease Neuroimaging Initiative. They underwent brain MRI scans, APOE genotyping, and completed up to six biannual Functional Activities Questionnaire (FAQ) assessments. Random effects regressions were used to examine trajectories of decline in FAQ across diagnostic groups, and to test the effects of ventricle-to-brain ratio (VBR) and APOE genotype on FAQ decline among MCI patients.
  
  
  RESULTS
  Rate of decline in FAQ among MCI patients was intermediate between that of controls and mild AD patients. Patients with MCI who converted to mild AD declined faster than those who remained stable. Among MCI patients, increased VBR and possession of any APOE varepsilon4 allele were associated with faster rate of decline in FAQ. In addition, there was a significant VBR by APOE varepsilon4 interaction such that patients who were APOE varepsilon4 positive and had increased atrophy experienced the fastest decline in FAQ.
  
  
  CONCLUSIONS
  Functional decline occurs in MCI, particularly among patients who progress to mild AD. Brain atrophy and APOE varepsilon4 positivity are associated with such declines, and patients who have elevated brain atrophy and are APOE varepsilon4 positive are at greatest risk of functional degradation. These findings highlight the value of genetic and volumetric MRI information as predictors of functional decline, and thus disease progression, in MCI.
authors.affiliation: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ozioma@jhmi.edu
authors.forename: Ozioma C
authors.initials: OC
authors.lastname: Okonkwo
authors.forename: Michael L
authors.initials: ML
authors.lastname: Alosco
authors.forename: Beth A
authors.initials: BA
authors.lastname: Jerskey
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Sweet
authors.forename: Brian R
authors.initials: BR
authors.lastname: Ott
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Tremont
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000235:genetics / Q000473:pathology; D053327:Apolipoprotein E4 / Q000235:genetics*; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000473:pathology*; D002552:Cerebral Ventricles / Q000473:pathology; D003072:Cognition Disorders / Q000150:complications / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D013223:Statistics as Topic; D011795:Surveys and Questionnaires
chemical_list: D053327:Apolipoprotein E4
references.citation: Invest Radiol. 2001 Sep;36(9):539-46
references.pmid: 11547042
references.citation: Neurology. 2005 Nov 8;65(9):1502-3
references.pmid: 16275849
references.citation: Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9
references.pmid: 9236950
references.citation: Ann Neurol. 2009 Apr;65(4):403-13
references.pmid: 19296504
references.citation: Neuropsychology. 2008 Jul;22(4):531-44
references.pmid: 18590364
references.citation: Neurology. 2001 May 8;56(9):1143-53
references.pmid: 11342678
references.citation: Cereb Cortex. 2004 Jan;14(1):11-22
references.pmid: 14654453
references.citation: J Neuropathol Exp Neurol. 2008 Apr;67(4):261-70
references.pmid: 18379441
references.citation: Pharmacogenomics J. 2010 Oct;10(5):375-84
references.pmid: 20029386
references.citation: J Neuropsychiatry Clin Neurosci. 2007 Summer;19(3):249-65
references.pmid: 17827410
references.citation: Radiology. 2008 Aug;248(2):590-8
references.pmid: 18574133
references.citation: Neuroscience. 1995 Dec;69(3):757-61
references.pmid: 8596645
references.citation: N Engl J Med. 2005 Jun 9;352(23):2379-88
references.pmid: 15829527
references.citation: J Int Neuropsychol Soc. 2007 Sep;13(5):747-57
references.pmid: 17521485
references.citation: Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 3:14-22
references.pmid: 10654095
references.citation: J Gerontol. 1982 May;37(3):323-9
references.pmid: 7069156
references.citation: Neurobiol Aging. 2010 Sep;31(9):1601-5
references.pmid: 18829136
references.citation: Neurology. 2007 Oct 9;69(15):1528-35
references.pmid: 17923615
references.citation: Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):14-24
references.pmid: 17334268
references.citation: Neurology. 2003 Aug 26;61(4):487-92
references.pmid: 12939422
references.citation: J Gerontol A Biol Sci Med Sci. 2005 Mar;60(3):324-33
references.pmid: 15860469
references.citation: Neurology. 2002 Mar 12;58(5):758-64
references.pmid: 11889240
references.citation: Alzheimers Dement. 2005 Jul;1(1):55-66
references.pmid: 17476317
references.citation: Neurology. 2005 Oct 25;65(8):1227-31
references.pmid: 16247049
references.citation: J Magn Reson Imaging. 2008 Apr;27(4):685-91
references.pmid: 18302232
references.citation: Br J Psychiatry. 2006 Nov;189:399-404
references.pmid: 17077428
references.citation: Neuroimage. 1999 Feb;9(2):179-94
references.pmid: 9931268
references.citation: Neurology. 2006 Aug 8;67(3):461-6
references.pmid: 16894108
references.citation: Br J Radiol. 2002 Jun;75(894):506-13
references.pmid: 12124237
references.citation: Biol Psychol. 2000 Oct;54(1-3):35-54
references.pmid: 11035219
references.citation: Neurocase. 2005 Feb;11(1):3-7
references.pmid: 15804918
references.citation: Nat Rev Neurosci. 2008 Oct;9(10):768-78
references.pmid: 18802446
references.citation: Neurology. 2005 Jul 12;65(1):119-24
references.pmid: 16009896
references.citation: Neurology. 1984 Jul;34(7):939-44
references.pmid: 6610841
references.citation: CNS Drugs. 2004;18(13):853-75
references.pmid: 15521790
references.citation: J Gerontol B Psychol Sci Soc Sci. 2007 Jan;62(1):P3-P11
references.pmid: 17284555
references.citation: Neuron. 2001 Oct 25;32(2):181-4
references.pmid: 11683989
references.citation: J Int Neuropsychol Soc. 2004 May;10(3):442-52
references.pmid: 15147601
references.citation: Arch Neurol. 2000 Jun;57(6):877-84
references.pmid: 10867786
references.citation: CNS Spectr. 2008 Jan;13(1):45-53
references.pmid: 18204414
references.citation: Arch Neurol. 2002 Jul;59(7):1154-60
references.pmid: 12117364
references.citation: Neurobiol Aging. 2009 Mar;30(3):432-40
references.pmid: 17869384
references.citation: Neuron. 2002 Jan 31;33(3):341-55
references.pmid: 11832223
references.citation: Arch Neurol. 2000 Mar;57(3):312-4
references.pmid: 10714654
references.citation: J Cell Mol Med. 2008 Dec;12(6B):2762-71
references.pmid: 18318693
references.citation: J Gerontol A Biol Sci Med Sci. 2005 Oct;60(10):1319-23
references.pmid: 16282567